明胶

Search documents
这头猪死了,但你还能在子弹、牛肉、金属、红酒和人类心脏里找到它
3 6 Ke· 2025-10-13 00:37
猪固有一死,或做成锅包肉,或做成卤猪蹄……且慢,一头猪死后,真的只有被端上餐桌这条去路吗? 荷兰有一头肉猪,它的生平虽不为人所知,但它全身各个部分的最终归宿都被记录下来。出人意料的是,它被加工成了足足185种产品——包括子弹、药 丸、牛肉等许多种我们完全料想不到的。 图 | christienmeindertsma.com 追踪这头猪的人是一位荷兰设计师,名叫克莉丝汀•梅因德斯玛(Christien Meindertsma)。2007年,她从荷兰养殖场随机选中了一头猪,记录下它死后的 全部经历,并出版了这本名叫"PIG 05049"的书籍。 这本书的封面设计十分朴素,但它但书脊上装饰着一件不同寻常的东西:一个亮黄色的圆形塑料标签。这其实是一个耳标,它用在养殖场中,是一头猪活 过的证明。而如果你从书架上抽下这本书,还会在它的封底看到一枚检疫章,这是一头猪死去的标志:它在屠宰场被宰杀,检疫合格,接下来就会变成商 品进入市场。 关于05049号猪死后的故事,就在这本书里。 "掺"进牛排的猪 首先,就像我们能想到的那样,05049号被加工成了各种各样的肉制品,这些肉制品在书中占去了近一半的篇幅。 这可能是书中最无聊的 ...
东宝生物(300239.SZ)未向骨胶水生产厂家供应原料
Ge Long Hui· 2025-09-17 07:02
格隆汇9月17日丨东宝生物(300239.SZ)在互动平台表示,公司主营明胶、胶原蛋白、空心胶囊及TOC端 系列产品,主要应用于医药、食品,营养大健康等领域。公司未向骨胶水生产厂家供应原料。 ...
专注天然胶原核心主线 东宝生物上半年实现营业收入3.69亿元
Zheng Quan Ri Bao Wang· 2025-08-29 10:27
Core Insights - Dongbao Biological achieved operating revenue of 369 million yuan and a net profit attributable to shareholders of 36.97 million yuan in the first half of 2025 [1] - The company focuses on the natural collagen sector and implements a health development strategy amid uncertainties in the external environment, particularly in the gelatin market [1][2] - Dongbao Biological is actively responding to market challenges through product segmentation, exploring new application fields, and enhancing digital transformation [1][2] Financial Performance - In the first half of 2025, Dongbao Biological's revenue was 369 million yuan, with a net profit of 36.97 million yuan [1] - The company faced short-term declines in sales and prices due to fluctuations in the gelatin market [1] Strategic Initiatives - Dongbao Biological is enhancing its research and development system, focusing on demand-driven innovation and application breakthroughs [2] - The company is advancing various projects, including specialized collagen for cashmere textiles and low-endotoxin gelatin, which are in the process of market engagement [2] - The company is also pushing for the industrialization of hair care collagen products and expanding its product matrix into multiple application fields [2][3] Market Positioning - Dongbao Biological is committed to developing high-value-added collagen derivatives, maintaining its leading position in the natural collagen industry [3] - The company aims to evolve into a comprehensive enterprise group in the health industry, focusing on medical, beauty, health, and food sectors [3]
今年前7个月,海口海关出口原产地签证货值超50亿元!
Sou Hu Cai Jing· 2025-08-19 23:35
Group 1 - In the first seven months of this year, Haikou Customs issued a total of 8,610 export certificates of origin for Hainan's foreign trade enterprises, with a total value of 5.06 billion yuan, representing year-on-year increases of 4.7% and 15.9% respectively [1][3] - The certificate of origin is a legal document that allows enterprises to enjoy tariff reductions under free trade agreements, significantly enhancing their competitiveness in international markets [3][4] - More than 220 foreign trade enterprises in Hainan, including Hainan Zhongxin Chemical Co., Ltd. and Hainan Jinpan Intelligent Technology Co., Ltd., have benefited from these certificates, facilitating the export of chemical products and electrical goods to markets such as RCEP member countries, ASEAN, and the EU [3][4] Group 2 - The use of the "smart review platform" by customs allows for 24/7 intelligent review of certificates of origin, significantly reducing the time required for document verification and expediting exports for enterprises [3][4] - Hainan Zhongxin Chemical Co., Ltd. has achieved a "zero out-of-home" application process for all certificates of origin, greatly reducing both time and economic costs associated with obtaining these documents [4] - Haikou Customs is conducting training sessions to help enterprises understand the rules and policies related to preferential trade arrangements, ensuring they can fully benefit from tariff reductions [4][5]
百年煤城转型“闯世界”:多元产业融入全球供应链
Zhong Guo Xin Wen Wang· 2025-08-09 06:53
Group 1: Industry Transformation - Jilin Qixing Aluminum Co., Ltd. is producing aluminum alloy components for Alstom trains, establishing a complete industrial chain in Liao Yuan, which is a key competitive advantage [1] - Qixing Aluminum holds over 50% market share in China's rail vehicle aluminum components and accounts for over 90% of the export share of similar products [1] - Liao Yuan, once a significant coal city, is transitioning to new industries to reduce reliance on coal, with companies like Qixing Aluminum finding new positions in the global supply chain [1] Group 2: Key Manufacturing Sectors - The automotive parts industry is also significant in Liao Yuan, with Fu'ao Automotive Parts Co., Ltd. exporting products to countries like the USA, Mexico, and Italy, generating an annual export revenue of approximately 200 million RMB [1] - The Liao Yuan sock industry comprises over 1,000 enterprises with an annual production of 3.5 billion pairs of cotton socks, accounting for about 25% of China's total output and 15% of the global market [2] - International capital is actively participating in Liao Yuan's economic transformation, exemplified by the investment of 700 million RMB by Germany's Gelita, which has established its largest production base in China for gelatin [2] Group 3: Economic Impact and Employment - The emergence of new manufacturing, textile, and food processing industries is not only generating tax revenue but also providing employment for thousands of former coal workers [2] - Local government initiatives have transformed abandoned industrial sites into parks and recreational areas, enhancing the livability of the region [2] - Positive feedback from international partners highlights Liao Yuan's attractive environment and quality of life, drawing comparisons to successful industrial transformations like that of the Ruhr area in Germany [2]
青岛富豪新棋局:年入近200亿仍陷短债压力,国恩股份赴港急上市
Sou Hu Cai Jing· 2025-07-29 12:18
Core Viewpoint - Guoen Co., Ltd. is striving for an IPO on the Hong Kong Stock Exchange to expand its global production capacity and address financial pressures due to rising debt levels and declining profit margins [1][2][8]. Group 1: Company Overview - Guoen Co., Ltd. is a leading player in the domestic chemical new materials industry, focusing on two main sectors: large chemicals and health [1]. - The company has a diverse product range, including collagen, hollow capsules, gelatin, and organic polymer materials, which are essential raw materials for pharmaceuticals, health products, home appliances, food, and some industrial products [1]. - Founded in 2000 by Wang Aiguo, Guoen has grown from a startup to a major industry leader, with annual revenues nearing 20 billion RMB [3][4]. Group 2: Financial Performance - The company's revenue increased from 750 million RMB in 2015 to 19.19 billion RMB in 2024, while net profit rose from 72.24 million RMB to 685 million RMB during the same period [6]. - However, the asset-liability ratio has surged from 28.36% in 2015 to 61.68% in 2024, with total liabilities increasing from 280 million RMB to 11.32 billion RMB, indicating a significant reliance on debt for expansion [8][9]. - As of the end of 2024, the company had cash and cash equivalents of 2.015 billion RMB, insufficient to cover short-term borrowings of 2.217 billion RMB, highlighting liquidity challenges [9][10]. Group 3: Market Challenges - Guoen's gross profit margin has been declining, from 14.75% in 2021 to 8.71% in 2024, which constrains profitability [15]. - The large chemicals segment faces intense competition and price wars, while the health segment is impacted by procurement pressures from downstream pharmaceutical companies [16]. - In Q1 2025, the company reported a revenue decline of 0.23% year-on-year, marking the first drop in nearly a decade, with net profit decreasing by 9.8% [16]. Group 4: Strategic Initiatives - The company plans to use the funds raised from the Hong Kong IPO to enhance its global production capacity, including establishing production bases in Thailand, Vietnam, and Mexico [2][19]. - Guoen aims to increase its overseas revenue share, which was only 1.58% in 2024, as part of its strategy to mitigate growth bottlenecks [19]. - The international expansion is seen as a necessary step to align with the global market demands and improve cost efficiency [19].
稀土高新区:“党建+”按下产业振兴加速键
Nei Meng Gu Ri Bao· 2025-07-24 13:45
Group 1 - The core focus of the news is on the role of party-building initiatives in driving technological advancements and operational efficiency in companies like Baotou Yinstar Rare Earth Magnetic New Materials Co., Ltd. and Baotou Dongbao Biotechnology Co., Ltd. [2][3] - Yinstar is working on a complex magnetic component that requires precise assembly of three differently shaped products, highlighting the company's commitment to innovation in the electronics sector [2] - Dongbao has established a three-tier responsibility system for party leadership, integrating party assessments with business performance metrics to enhance operational effectiveness [3] Group 2 - Dongbao emphasizes the importance of collaboration with academic institutions, such as the Chinese Academy of Sciences, to facilitate the practical application of theoretical research, thereby accelerating technology transfer [5] - The company has successfully transitioned from traditional manufacturing to intelligent manufacturing, achieving significant breakthroughs in gelatin and collagen production [5] - The Baotou Rare Earth High-tech Zone is leveraging party-building to reconstruct industrial, innovation, and talent chains, enhancing the overall development efficiency of the region [6]
国恩股份(002768):深化“一体两翼”布局,业绩或进入放量期
NORTHEAST SECURITIES· 2025-07-18 09:28
Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][7]. Core Views - The company is enhancing its integrated industrial chain in the large chemical sector, which is expected to boost future profitability through various strategic projects [2]. - In the health sector, the company is focusing on collagen products and expanding its hollow capsule production capacity, anticipating significant growth in performance [3]. - The overall performance is projected to enter a growth phase, with expected net profits of 742 million, 947 million, and 1,095 million yuan for the years 2025, 2026, and 2027 respectively [3]. Summary by Relevant Sections Large Chemical Sector - The company is extending its upstream industrial chain in chemical new materials, with projects such as a 1 million tons/year polystyrene project and a 200,000 tons/year high-performance polyolefin elastomer project [2]. - The focus is on achieving cost advantages through scale effects and enhancing the complete industrial chain from monomers to end products [2]. Health Sector - The company holds a leading position in the collagen field through its subsidiary Dongbao Biological, which has an annual production capacity of 13,500 tons of gelatin [3]. - The hollow capsule production capacity is set to expand significantly, with a projected output of nearly 70 billion capsules annually, positioning the company as a major player in this market [3]. Financial Projections - Revenue is expected to grow from 19,220 million yuan in 2024 to 28,646 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 14.23% [5]. - The net profit is projected to increase from 676 million yuan in 2024 to 1,095 million yuan in 2027, indicating a strong growth trajectory [5]. - The report estimates a price-to-earnings (P/E) ratio of 12.57X for 2025, decreasing to 8.52X by 2027, suggesting improving valuation metrics [5].
东宝生物: 2023年包头东宝生物技术股份有限公司向不特定对象发行可转换公司债券2025年跟踪评级报告
Zheng Quan Zhi Xing· 2025-06-20 10:17
Core Viewpoint - The company maintains a stable credit rating outlook while facing challenges such as declining revenue and net profit due to changes in downstream industry policies and market fluctuations [3][5][6]. Company Overview - The company, Baotou Dongbao Biotechnology Co., Ltd., has acquired full ownership of Qingdao Yiqing Biotechnology Co., Ltd., enhancing its vertical integration in the gelatin and hollow capsule industries [3][5]. - The company specializes in the research, production, and sales of gelatin, collagen, hollow capsules, and related products, with a focus on expanding its market presence [5][20]. Financial Performance - For 2024, the company reported total assets of 25.92 billion, total liabilities of 6.26 billion, operating income of 1.88 billion, and net profit of 0.19 billion [3][4]. - The company's revenue and net profit have shown a year-on-year decline due to price reductions in gelatin products and inventory destocking by customers [5][16]. - The operating cash flow remains positive, indicating a stable cash position despite the revenue decline [24]. Industry Environment - The gelatin and collagen industries are experiencing increased regulatory scrutiny, leading to market consolidation and heightened competition among manufacturers [11][12]. - The hollow capsule market is closely tied to the pharmaceutical industry, with growing demand driven by increased health awareness and changing medication habits among consumers [14][15]. Production and Capacity - The company has a gelatin production capacity of 13,500 tons per year, with a utilization rate of 72.07% in 2024, reflecting a decrease from the previous year [16][17]. - The hollow capsule production capacity has increased to 360 billion capsules per year, with a production volume of 304.42 billion capsules in 2024 [21][22]. Risks and Challenges - The company faces risks related to the realization of returns from ongoing projects and the potential for underutilization of production capacity [6][23]. - High equity pledge rates among major shareholders pose a risk of forced liquidation, which could impact the company's financial stability [7][20].
国恩股份:拟发行H股申请在港交所上市
Sou Hu Cai Jing· 2025-05-29 07:23
Core Viewpoint - On May 26, 2025, Guoen Technology Co., Ltd. announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operations and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1][5]. Group 1: H-Share Issuance and Listing - The company plans to issue H-shares not exceeding 15% of the total share capital post-issuance, with proceeds allocated for establishing a Hong Kong regional headquarters, R&D investments, capacity expansion, strategic investments, and operational funding [1][5]. - The issuance and listing are subject to shareholder approval and regulatory approvals [1]. Group 2: Management Changes - On the same day, the company announced the resignation of two board members, Zhang Shide and Liu Shuyuan, due to personal reasons, with no impact on the board's legal quorum [1][2]. Group 3: Company Overview and Financial Performance - Founded in December 2000 and listed in June 2015, Guoen Group has developed a diversified portfolio in green petrochemicals, organic polymers, and health-related products, among others [4]. - In 2024, the company reported revenue of 19.219 billion yuan, a 10.21% increase from the previous year, and a net profit of 676 million yuan, up 45.18% year-on-year [4]. - The chemical industry segment generated 17.369 billion yuan, accounting for 90.38% of total revenue, while the health industry segment saw a decline in revenue [4]. Group 4: Recent Financial Results - In Q1 2025, the company reported revenue of 4.412 billion yuan, a slight decrease of 0.23%, and a net profit of 111 million yuan, down 9.79% year-on-year [5]. - As of March 31, 2025, total assets were 18.971 billion yuan, a 23.71% increase year-on-year, while total liabilities rose by 34.64% to 11.866 billion yuan [5].